The Scientist

» biobusiness

Most Recent

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

4 Comments

image: Cannabis Biotech

Cannabis Biotech

By | December 1, 2014

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

2 Comments

image: LabCorp Buys CRO

LabCorp Buys CRO

By | November 4, 2014

The $6 billion deal marks yet another massive transaction in the health-care industry.

1 Comment

image: Merck Buys Sigma-Aldrich for $17B

Merck Buys Sigma-Aldrich for $17B

By | September 22, 2014

Two giants merge as the German drug maker acquires the US-based science supply company.

1 Comment

image: Banking on iPSCs

Banking on iPSCs

By | September 1, 2014

A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.

0 Comments

image: Keeping Up with IP

Keeping Up with IP

By | September 1, 2014

It’s never too early to start thinking about intellectual property rights—even for biologists doing basic research.

0 Comments

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: 2014 Salary Survey Closed

2014 Salary Survey Closed

By | July 14, 2014

Check back for the results in November!

3 Comments

image: Banking on iPSCs

Banking on iPSCs

By | June 30, 2014

A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS